JW Cayman Therapeutics Co. Ltd. announced a major transaction involving Amendment No. 1 to its Collaboration Agreement. The amendment, dated October 30, 2025, involves JW Cayman, JW Shanghai, and Regeneron. Under the terms of the amendment, Regeneron has agreed to fund certain development activities related to the MAGE-A4 Product, including making an upfront payment to the company. The collaboration agreement was originally established between JW Cayman and 2seventy bio on October 27, 2022, and was assigned to Regeneron effective April 1, 2024.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JW Cayman Therapeutics Co. Ltd. published the original content used to generate this news brief on October 30, 2025, and is solely responsible for the information contained therein.